Novo Nordisk has a lot riding on new diabetes therapy Ozempic, and says the once-weekly drug has made good headway in the US since its launch in February. Widely considered a blockbuster-in-waiting, Ozempic (semaglutide) had sales of 264m krone ($41m) in the first half of the year, suggesting that the Danish drugmaker is making quick
Novo Nordisk has acquired its first global approval for its once-weekly diabetes therapy Ozempic in the US. The FDA has approved the drug’s use alongside diet and exercise to improve glycaemic control in adults with type II diabetes. Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist that induced clinically meaningful and statistically significant reductions
Novo Nordisk has stated that it will maximise efforts to treat obesity – a major cause of diabetes – as it moves forward with a clinical study. With its established diabetes treatments in the firing line, especially due to U.S. price pressures, Novo Nordisk is pinning hopes for growth on expanding its obesity franchise. Novo’s
A study, conducted by Boston-based Reputation Institute, collated more than 16,500 reputation ratings collected throughout the U.S., Europe and Brazil during first two months of this year has ranked AbbVie No. 1. Who is then closely followed by Novo Nordisk and Takeda, who edged out rivals from a group of 17 companies to earn spots
